<?xml version="1.0" encoding="UTF-8"?>
<p class="p">Talinolol (TAL) [1-(4-cyclohexylureido-phenoxy)-2-hydroxy- 3-tert-butylaminopropane] (
 <xref ref-type="fig" rid="F1" class="xref">Figure 1</xref>) is a long-acting, highly selective β
 <sub class="sub">1</sub> -adrenergic receptor antagonist which is incompletely absorbed in human from the upper small intestine (
 <xref rid="B26" ref-type="bibr" class="xref">Schwarz et al., 2000</xref>; 
 <xref rid="B31" ref-type="bibr" class="xref">Siegmund et al., 2003</xref>). TAL (MW 363.49) is a moderately lipophilic molecule (log P: 3.2) with ionizable groups (pKa: 9.4). The solubility of TAL is pH dependent with low solubility at higher pH (0.02 mg/ml at pH 7.4, 37°C) (
 <xref rid="B34" ref-type="bibr" class="xref">Trausch et al., 1995a</xref>). It has moderate lipophilic properties compared with other β-blockers (
 <xref rid="B34" ref-type="bibr" class="xref">Trausch et al., 1995a</xref>; 
 <xref rid="B20" ref-type="bibr" class="xref">Pathak et al., 2010</xref>). The commercial product of TAL (Cordanum
 <sup class="sup">®</sup>) has been frequently used in Germany and Eastern Europe for almost five decades for the treatment of anxiety, hypertension, angina pectoris, cardiac arrhythmias, glaucoma, and migraine headaches with oral doses of 50 to 300 mg per day (
 <xref rid="B37" ref-type="bibr" class="xref">Wetterich et al., 1996</xref>; 
 <xref rid="B2" ref-type="bibr" class="xref">Chiou et al., 2001</xref>; 
 <xref rid="B1" ref-type="bibr" class="xref">Awadallah et al., 2003</xref>).
</p>
